表紙
市場調査レポート

米国の個人化癌ゲノムシークエンシング市場

US Personalized Cancer Genome Sequencing Market Outlook 2018

発行 RNCOS E-Services Pvt. Ltd. 商品コード 250711
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
米国の個人化癌ゲノムシークエンシング市場 US Personalized Cancer Genome Sequencing Market Outlook 2018
出版日: 2014年03月01日 ページ情報: 英文 65 Pages
概要

全ゲノムシークエンシング技術は過去10年間に空前の速度で発展しました。バイオインフォマティクスに基づくデータ解析用のシーケンシング・プラットフォームや、個人化医療への適用などの動きと並行して、特定ゲノムシークエンシングから全ゲノムシークエンシングへの技術進歩が急速に進められてきました。また、全ゲノムシークエンシングは癌治療のための新たなブレークスルーであることも分かってきました。新手法の開発により、ゲノムデータを癌の個別化医療に適用することが可能となり、それが全ゲノムシークエンシングのコストの大幅引き下げにつながりました。

当レポートでは、米国における個人化された癌ゲノムシークエンシング市場の中でも、全ゲノムシークエンシングの分野について分析し、米国の癌の有病率・発病率の状態(過去4年間の実績値と今後5年間の予測値)や、潜在的・顕示的な市場規模の見通し、関連規制の動向、克服すべき課題、関連企業のプロファイルを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 アナリストの見解

第2章 分析手法

第3章 ゲノムシークエンシング:概略

第4章 癌患者の人口統計

  • 有病率・発病率・死亡率(通算9年間分)
  • 発病率の高い州
  • 発病率の高い癌の種類
    • 男性の癌発病率
    • 女性の癌発病率
    • 年齢層別

第5章 米国の個人化癌全ゲノムシークエンス:潜在的市場

第6章 米国の個人化癌全ゲノムシークエンス:現在および将来の市場分析

第7章 規制に関する考察

  • 臨床検査室改善法(CLIA)による認定
  • 米国病理学者協会(CAP)による認定

第8章 市場の抑制要因

第8章 競合企業の評価

  • Illumina
    • 事業概要
    • 主要データ
    • 強み・弱み
  • Complete Genomics
  • Beckman Coulter Genomics
  • Expression Analysis
  • EdgeBio
  • Foundation Medicine
  • SeqWright
  • Ambry Genetics
  • BGI Americas Corporation
  • Cofactor Genomics

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing.

Our report entitled “US Personalized Cancer Genome Sequencing Market Outlook 2018” entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018.

The said advanced technology has potential to revolutionize the field of medicine. We have closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, we have also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.

The report analyzes the competitive landscape of the market by properly analyzing the business, services and activities of the companies such as Illumina, Complete Genomics, and Ambry Genetics. It also provides the competitive benchmarking, taking into account key information such as market value, revenues, risk score etc., along with the strengths and weaknesses of each player. Overall, the report is a complete source of knowledge and statistics for clients who want to get an in-depth understanding of the market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Genome Sequencing: An Introduction

4. Cancer Statistics by Demographics

  • 4.1. Prevalence, Incidences, and Mortality (2010-2018)
  • 4.2. Leading States by Incidence
  • 4.3. Leading Cancers by Incidence
    • 4.3.1. Male Cancer Incidences
    • 4.3.2. Female Cancer Incidences
    • 4.3.3. Age-Group

5. US Personalized Cancer WGS Potential Market to 2018

6. US Personalized Cancer WGS: Current and Future Market Analysis

7. Regulatory Insights

  • 7.1. Clinical Laboratory Improvement Amendments (CLIA) Accreditation
  • 7.2. CAP Accreditation

8. Market Constraints

9. Competitive Assessment

  • 9.1. Illumina
    • 9.1.1. Business Overview
    • 9.1.2. Key Information
    • 9.1.3. Strengths and Weaknesses
  • 9.2. Complete Genomics
    • 9.2.1. Business Overview
    • 9.2.2. Key Information
    • 9.2.3. Strengths and Weaknesses
  • 9.3. Beckman Coulter Genomics
    • 9.3.1. Business Overview
    • 9.3.2. Key Information
    • 9.3.3. Strengths and Weaknesses
  • 9.4. Expression Analysis
    • 9.4.1. Business Overview
    • 9.4.2. Key Information
    • 9.4.3. Strengths and Weaknesses
  • 9.5. EdgeBio
    • 9.5.1. Business Overview
    • 9.5.2. Key Information
    • 9.5.3. Strengths and Weaknesses
  • 9.6. Foundation Medicine
    • 9.6.1. Business Overview
    • 9.6.2. Key Information
    • 9.6.3. Strengths and Weaknesses
  • 9.7. SeqWright
    • 9.7.1. Business Overview
    • 9.7.2. Key Information
    • 9.7.3. Strengths and Weaknesses
  • 9.8. Ambry Genetics
    • 9.8.1. Business Overview
    • 9.8.2. Key Information
    • 9.8.3. Strengths and Weaknesses
  • 9.9. BGI Americas Corporation
    • 9.9.1. Business Overview
    • 9.9.2. Key Information
    • 9.9.3. Strengths and Weaknesses
  • 9.10. Cofactor Genomics
    • 9.10.1. Business Overview
    • 9.10.2. Key Information
    • 9.10.3. Strengths and Weaknesses

List of Figures:

  • Figure 3-1: Schematic Diagram of Sequencing used for Human Genome Project
  • Figure 3-2: Long-range Sequence Assembly in Whole Genome Shotgun Sequencing
  • Figure 4-1: Cancer Prevalence (Million), 2010-2018
  • Figure 4-2: Cancer Incidences (Million), 2010-2018
  • Figure 4-3: Cancer Mortality (‘000), 2010-2018
  • Figure 4-4: Incidences by Type of Cancer (%), 2014
  • Figure 4-5: Cancer Incidences by Age Group (%), 2010
  • Figure 5-1: Number of People earning > US$ 100K (2009-2012)
  • Figure 5-2: Potential Customers for Personalized Cancer WGS Market (Billion), 2013-2018
  • Figure 5-3: Potential Customers for Personalized Cancer WGS Market by Age-Group (%), 2014
  • Figure 5-4: Potential Market for Personalized Cancer WGS (Billion US$), 2013-2018
  • Figure 6-1: Tapped and Untapped Personalized Cancer WGS Market (%), 2014
  • Figure 6-2: Personalized Cancer WGS Market (Million US$), 2013-2018

List of Tables:

  • Table 4-1: Top Ten States with Highest Cancer Incidences (‘000), 2014
  • Table 4-2: Top Ten Cancer Incidences in Males (2014)
  • Table 4-3: Top Ten Cancer Incidences in Females (2014)
  • Table 5-1: Top Ten States with Households earning > US$ 100K (2012)
  • Table 5-2: Key Demographics and Potential Customers for Personalized Cancer WGS Market (2014)
  • Table 5-3: Potential States for Personalized Cancer Whole Genome Sequencing
  • Table 9-1: Illumina - Key information
  • Table 9-2: Complete Genomics - Key Information
  • Table 9-3: Beckman Coulter Genomics - Key Information
  • Table 9-4: Expression Analysis - Key Information
  • Table 9-5: Edge Bio - Key Information
  • Table 9-6: Foundation Medicine - Key Information
  • Table 9-7: SeqWright - Key Information
  • Table 9-8: Ambry Genetics - Key Information
  • Table 9-9: BGI Americas Corporation - Key Information
  • Table 9-10: Cofactor Genomics - Key Information
Back to Top